In The News

 

  • Quoted in “Fed. Cir. Denies ‘Dolly’ Clone Rehearing; Supreme Court Only Option Available,” Bloomberg BNA Life Sciences Law & Industry Report (August 15, 2014)
  • Quoted in “Biotech Reels Over Natural Products Ruling,” Scientific American (July 9, 2014)
  • Quoted in “Biotech Reels Over Patent Ruling,” Nature (July 8, 2014) 
  • Quoted in “PTO’s Mayo/Myriad Eligibility Guidance May Chill New Drugs, Diagnostics, Panels Says,” Pharmaceutical Law & Industry Report (July 1, 2014) 
  • Quoted in “Analysis: Myriad, Mayo Fuel Biopharma Patent Rejections,” SCRIP Intelligence (June 27, 2014) 
  • Quoted in “USPTO Extends Deadline to Comment on Subject Matter Eligibility Analysis,” Personalized Medicine Bulletin (June 26, 2014) 
  • Quoted in “Bloomberg BNA Study Analyzes the Impact of Recent Supreme Court Decisions that Leave Life Sciences Industry Under Cloud of Uncertainty: Report Released at 2014 BIO International Convention Explores Important Changes to Patent Process,” BioMedReports, PR Newswire, IT Business Net, Congoo, Bloomberg BNA (June 25, 2014) 
  • Quoted in “PTO’s Mayo/Myriad Eligibility Guidance May Chill New Drugs, Diagnostics, Panel Says,” Bloomberg BNA Medical Research Law & Policy Report (July 2, 2014) 
  • Quoted in “5 Recent Fed. Circ. Rulings IP Attys Need to Know,” Law360 (January 9, 2014) 
  • Quoted in “Stem Cell Patent Case Will be Early Test of Myriad’s Reach,” Law360 (July 10, 2013) 
  • On June 13, 2013, Mr. McFarlane was quoted in numerous publications and news sources for his comment on the Supreme Court’s ruling that isolated human genes cannot be patented.

CBS News

Law360